Should I buy or sell AcelRx Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRX shares. View ACRX analyst ratings or view top-rated stocks .

What is AcelRx Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 12 month target prices for AcelRx Pharmaceuticals' shares. Their ACRX share price targets range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next year. This suggests a possible upside of 457.2% from the stock's current price. View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts .

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 on January 1st, 2023. Since then, ACRX stock has decreased by 63.3% and is now trading at $0.83. View the best growth stocks for 2023 here .

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ACRX earnings forecast .

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The specialty pharmaceutical company had revenue of $0.12 million for the quarter.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals shares reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD) , Novavax (NVAX) , Amarin (AMRN) , Amicus Therapeutics (fold) , Inovio Pharmaceuticals (INO) , TG Therapeutics (TGTX) , OPKO Health (OPK) , CyberArk Software (CYBR) , Flexion Therapeutics (FLXN) and NVIDIA (NVDA) .

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (0.71%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti. View institutional ownership trends .

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX)

$0.83

+0.07 (+9.21%)

(As of 12/4/2023 ET)

Compare

Today's Range: $0.75
▼
$0.84
50-Day Range: $0.46
▼
$0.83
52-Week Range: $0.43
▼
$2.78

Volume: 79,693 shs
Average Volume: 206,114 shs
Market Capitalization: $14.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.63

AcelRx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 457.2% Upside
$4.63 Price Target
Short Interest: Healthy
4.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.41
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$8,000 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.40) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

125th out of 952 stocks

Pharmaceutical Preparations Industry

42nd out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
AcelRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.63, AcelRx Pharmaceuticals has a forecasted upside of 457.2% from its current price of $0.83.
Amount of Analyst Coverage
AcelRx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.68% of the float of AcelRx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
AcelRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AcelRx Pharmaceuticals has recently decreased by 1.12%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
AcelRx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AcelRx Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for AcelRx Pharmaceuticals is -2.41.

3.8

News and Social Media Coverage

News Sentiment
AcelRx Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
Search Interest
22 people have searched for ACRX on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.
MarketBeat Follows
3 people have added AcelRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AcelRx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.00% of the stock of AcelRx Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 19.79% of the stock of AcelRx Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AcelRx Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AcelRx Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AcelRx Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

ACRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACRX Stock News Headlines

November 25, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) Receives New Coverage from Analysts at StockNews.com

November 22, 2023 | msn.com

AcelRx Pharmaceuticals files for $150M mixed shelf

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | finanznachrichten.de

AcelRx Pharmaceuticals, Inc.: AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 7, 2023 | msn.com

AcelRx Pharmaceuticals Q3 2023 Earnings Preview

November 7, 2023 | finance.yahoo.com

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

October 26, 2023 | finance.yahoo.com

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

October 3, 2023 | finance.yahoo.com

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

September 12, 2023 | msn.com

AcelRx CEO buys 10,000 shares

September 12, 2023 | finance.yahoo.com

Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc

August 22, 2023 | finance.yahoo.com

What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock

August 18, 2023 | markets.businessinsider.com

Positive Report for Acelrx (ACRX) from H.C. Wainwright

August 13, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript

August 12, 2023 | finanznachrichten.de

AcelRx Pharmaceuticals, Inc.: AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 11, 2023 | finance.yahoo.com

Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call

August 11, 2023 | finance.yahoo.com

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 11, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates

July 28, 2023 | finance.yahoo.com

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

July 21, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

July 18, 2023 | seekingalpha.com

AcelRx Pharmaceuticals launches ~$10M private placement of shares

July 18, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

June 17, 2023 | finance.yahoo.com

ACRX - AcelRx Pharmaceuticals, Inc.

June 16, 2023 | fool.com

AcelRx Pharmaceuticals (NASDAQ: ACRX)

May 13, 2023 | finanznachrichten.de

AcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | msn.com

Recap: AcelRx Pharmaceuticals Q1 Earnings

May 10, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

See More Headlines

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACRX
CUSIP: N/A
CIK: 1427925
Web: www.acelrx.com
Phone: (650) 216-3500
Fax: 650-216-6500
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.63
High Stock Price Target: $5.00
Low Stock Price Target: $4.25
Potential Upside/Downside: +457.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $47.76 million
Net Margins: N/A
Pretax Margin: -3,711.25%
Return on Equity: -81.54%
Return on Assets: -46.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.04
Quick Ratio: 4.04

Sales & Book Value

Annual Sales: $1.77 million
Price / Sales: 7.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.65 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 16,950,000
Free Float: 16,443,000
Market Cap: $14.07 million
Optionable: Optionable
Beta: 0.64

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Vincent J. Angotti (Age 55)
CEO & Director
Comp: $906.54k
Dr. Pamela Pierce Palmer M.D. (Age 60)
Ph.D., Co-Founder, Chief Medical Officer & Director
Comp: $699.75k
Mr. Raffi Mark Asadorian (Age 54)
Chief Financial Officer
Comp: $637.5k
Mr. Anil N. Dasu (Age 60)
Chief Engineering Officer
Comp: $478.09k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRX Stock Analysis - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings or view top-rated stocks.
What is AcelRx Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 12 month target prices for AcelRx Pharmaceuticals' shares. Their ACRX share price targets range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next year. This suggests a possible upside of 457.2% from the stock's current price.
View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts.
How have ACRX shares performed in 2023?: AcelRx Pharmaceuticals' stock was trading at $2.26 on January 1st, 2023. Since then, ACRX stock has decreased by 63.3% and is now trading at $0.83.
View the best growth stocks for 2023 here.
When is AcelRx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ACRX earnings forecast.
How were AcelRx Pharmaceuticals' earnings last quarter?: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The specialty pharmaceutical company had revenue of $0.12 million for the quarter.

When did AcelRx Pharmaceuticals' stock split?: AcelRx Pharmaceuticals shares reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of AcelRx Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).
Who are AcelRx Pharmaceuticals' major shareholders?: AcelRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (0.71%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti.
View institutional ownership trends.
How do I buy shares of AcelRx Pharmaceuticals?: Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACRX) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX)

AcelRx Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

ACRX Stock Price History

ACRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™